产品
编 号：F286788
分子式：C9H11NO5
分子量：213.19
分子式：C9H11NO5
分子量：213.19
产品类型
规格
价格
是否有货
5mg
576
In-stock
10mg
768
In-stock
50mg
1760
In-stock
100mg
询价
询价
结构图
CAS No: 23651-95-8
产品详情
生物活性：
Droxidopa (L-DOPS; SM5688) is a potent, orally active norepinephrine precursor. Droxidopa increases standing blood pressure, ameliorates symptoms of orthostatic hypotension and improves standing ability. Droxidopa has the potential for the research of neurogenic orthostatic hypotension (nOH) and alternative ADHD (attention deficit hyperactivity disorder).
体内研究：
Droxidopa (200 mg/kg;i.p.) alters dopamine neuron and prefrontal cortex activity and improves attention-deficit/hyperactivity disorder-like behaviors in rats.Droxidopa (10, 20 mg/kg; i.p.) significantly increases the paw withdrawal latency and inhibits mechanical hypersensitivity to thermal stimulation in 6-OHDA-lesioned rats at the 5th week after surgery.Animal Model:250-380g male Sprague-Dawley rats
Dosage:200 mg/kg (10 mg/kg, i.p. benserazide was given to the animals at 20 or 30 min prior to L-DOPS injection)
Administration:I.p.
Result:Significantly decreased hyperactivity of BZ-pretreated SHR/NCrl at 30 (P < 0.01) and 40 min (P < 0.05) post-injection, improved inattention-like behavior of SHR/NCrl, and ameliorated impulsive-like behavior of SHR/NCrl and Wistar rats.
Droxidopa (L-DOPS; SM5688) is a potent, orally active norepinephrine precursor. Droxidopa increases standing blood pressure, ameliorates symptoms of orthostatic hypotension and improves standing ability. Droxidopa has the potential for the research of neurogenic orthostatic hypotension (nOH) and alternative ADHD (attention deficit hyperactivity disorder).
体内研究：
Droxidopa (200 mg/kg;i.p.) alters dopamine neuron and prefrontal cortex activity and improves attention-deficit/hyperactivity disorder-like behaviors in rats.Droxidopa (10, 20 mg/kg; i.p.) significantly increases the paw withdrawal latency and inhibits mechanical hypersensitivity to thermal stimulation in 6-OHDA-lesioned rats at the 5th week after surgery.Animal Model:250-380g male Sprague-Dawley rats
Dosage:200 mg/kg (10 mg/kg, i.p. benserazide was given to the animals at 20 or 30 min prior to L-DOPS injection)
Administration:I.p.
Result:Significantly decreased hyperactivity of BZ-pretreated SHR/NCrl at 30 (P < 0.01) and 40 min (P < 0.05) post-injection, improved inattention-like behavior of SHR/NCrl, and ameliorated impulsive-like behavior of SHR/NCrl and Wistar rats.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备